- Home
- EVC vs PBYI Comparison
EVC vs PBYI Comparison
Compare EVC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVC
- PBYI
- Stock Information
- Founded
- EVC 1996
- PBYI 2010
- Country
- EVC United States
- PBYI United States
- Employees
- EVC N/A
- PBYI N/A
- Industry
- EVC Broadcasting
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- EVC Industrials
- PBYI Health Care
- Exchange
- EVC Nasdaq
- PBYI Nasdaq
- Market Cap
- EVC 166.9M
- PBYI 176.1M
- IPO Year
- EVC 2000
- PBYI N/A
- Fundamental
- Price
- EVC $1.94
- PBYI $2.32
- Analyst Decision
- EVC Hold
- PBYI Strong Buy
- Analyst Count
- EVC 1
- PBYI 1
- Target Price
- EVC $1.75
- PBYI $7.00
- AVG Volume (30 Days)
- EVC 306.1K
- PBYI 393.6K
- Earning Date
- EVC 10-31-2024
- PBYI 10-31-2024
- Dividend Yield
- EVC 10.13%
- PBYI N/A
- EPS Growth
- EVC N/A
- PBYI N/A
- EPS
- EVC N/A
- PBYI 0.18
- Revenue
- EVC $1,126,331,000.00
- PBYI $219,143,000.00
- Revenue This Year
- EVC N/A
- PBYI N/A
- Revenue Next Year
- EVC N/A
- PBYI N/A
- P/E Ratio
- EVC N/A
- PBYI $12.75
- Revenue Growth
- EVC 65.95
- PBYI N/A
- 52 Week Low
- EVC $1.33
- PBYI $2.13
- 52 Week High
- EVC $4.41
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- EVC 47.02
- PBYI 34.73
- Support Level
- EVC $1.89
- PBYI $2.23
- Resistance Level
- EVC $2.08
- PBYI $2.56
- Average True Range (ATR)
- EVC 0.08
- PBYI 0.17
- MACD
- EVC 0.00
- PBYI -0.01
- Stochastic Oscillator
- EVC 20.00
- PBYI 14.06
About EVC Entravision Communications Corporation
Entravision Communications Corp is a global advertising solutions, media, and technology company. Its operations encompass integrated marketing and media solutions, comprised of television, radio, and digital properties and data analytics services. The company operates in television broadcasting, audio broadcasting, and digital media segments. The Company's digital segment, whose operations are located in Europe, Latin America, Asia, the United States, and Africa. The Company's television and audio operations reach and engage U.S. Hispanics in the United States.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.